NASDAQ:BDRX Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis $1.56 +0.14 (+9.86%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Biodexa Pharmaceuticals Stock (NASDAQ:BDRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BDRX alerts:Sign Up Key Stats Today's Range$1.42▼$1.6050-Day Range$1.20▼$4.3252-Week Range$1.14▼$74.00Volume119,085 shsAverage Volume596,730 shsMarket Capitalization$57.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBiodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Read More… Biodexa Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreBDRX MarketRank™: Biodexa Pharmaceuticals scored higher than 4% of companies evaluated by MarketBeat, and ranked 892nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Biodexa Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Biodexa Pharmaceuticals are expected to remain at ($1.25) per share in the coming year.Price to Book Value per Share RatioBiodexa Pharmaceuticals has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.19% of the float of Biodexa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverBiodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodexa Pharmaceuticals has recently increased by 10.31%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiodexa Pharmaceuticals does not currently pay a dividend.Dividend GrowthBiodexa Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.19% of the float of Biodexa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverBiodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodexa Pharmaceuticals has recently increased by 10.31%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Biodexa Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for BDRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Biodexa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biodexa Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.34% of the stock of Biodexa Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 17.51% of the stock of Biodexa Pharmaceuticals is held by institutions.Read more about Biodexa Pharmaceuticals' insider trading history. Receive BDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BDRX Stock News HeadlinesWhat Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy StockApril 24 at 9:08 PM | msn.comNotice of General MeetingApril 17, 2025 | globenewswire.comIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.April 24, 2025 | Porter & Company (Ad)Preliminary Results for the Year Ended 31 December 2024April 11, 2025 | globenewswire.comBiodexa says on track to initiate Phase 3 trial in FAP next quarterMarch 20, 2025 | markets.businessinsider.comBiodexa Pharmaceuticals PLC Achieves Key Milestone with FDA Following Type C Meeting for Phase 3 eRapa Study in Familial Adenomatous PolyposisMarch 12, 2025 | nasdaq.comBiodexa Pharma To Initiate Registrational Phase 3 Study Of ERapa In FAP In Next QuarterMarch 12, 2025 | nasdaq.comBiodexa Pharmaceuticals PLC: Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAPMarch 10, 2025 | finanznachrichten.deSee More Headlines BDRX Stock Analysis - Frequently Asked Questions How have BDRX shares performed this year? Biodexa Pharmaceuticals' stock was trading at $4.05 at the start of the year. Since then, BDRX shares have decreased by 61.5% and is now trading at $1.56. View the best growth stocks for 2025 here. How were Biodexa Pharmaceuticals' earnings last quarter? Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) announced its quarterly earnings data on Thursday, September, 10th. The company reported ($1,600.00) earnings per share (EPS) for the quarter. When did Biodexa Pharmaceuticals' stock split? Biodexa Pharmaceuticals shares reverse split on Friday, October 4th 2024. The 1-25 reverse split was announced on Thursday, September 19th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Biodexa Pharmaceuticals? Shares of BDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biodexa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biodexa Pharmaceuticals investors own include SoundHound AI (SOUN), Dyne Therapeutics (DYN), NVIDIA (NVDA), Viking Therapeutics (VKTX), TRACON Pharmaceuticals (TCON), ASE Technology (ASX) and BigBear.ai (BBAI). Company Calendar Last Earnings9/10/2020Today4/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BDRX Previous SymbolLON:MTPH CIK1643918 Webwww.midatechpharma.com Phone441235888300FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.02 Current Ratio2.16 Quick RatioN/A Sales & Book Value Annual Sales$83,000.00 Price / Sales686.85 Cash FlowN/A Price / Cash FlowN/A Book Value$42.56 per share Price / Book0.04Miscellaneous Outstanding Shares36,544,000Free Float36,420,000Market Cap$57.01 million OptionableNot Optionable Beta1.70 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:BDRX) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersTop Picks for Trump’s Pro-Crypto AmericaJust Announced: What Trump’s Move Means for Crypto—Join Now 27 top names reveal urgent insights as Bitcoin ...Crypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.